1Significance and evaluation of novel molecular diagnosis methods for early lung cancerWANG Zi-qi, ZHANG Xiao-juSYMPOSIUM·DIAGNOSIS AND TREATMENT OF LUNG CANCER449-4532Controversies and consensuses on neoadjuvant therapy for lung cancerJIN Yi-nuo, WANG QiSYMPOSIUM·DIAGNOSIS AND TREATMENT OF LUNG CANCER454-4623Application and selection of respiratory interventional techniques in the diagnosis and treatment of lung cancerYANG Lin-hui, LIU DanSYMPOSIUM·DIAGNOSIS AND TREATMENT OF LUNG CANCER463-4704Strategies for balancing the efficacy and immune-related adverse events in personalized immunotherapy for advanced lung cancerWANG Li-qiang, XIE Xiao-hong, LIN Xin-qing, ZHOU Cheng-zhiSYMPOSIUM·DIAGNOSIS AND TREATMENT OF LUNG CANCER471-4765Prevention and treatment of common complications in advanced lung cancerWANG Shuang, LU Yu-ke, LI En-chengSYMPOSIUM·DIAGNOSIS AND TREATMENT OF LUNG CANCER477-4836Chongqing expert consensus on biologics treatment for type 2 inflammatory asthmaThe Development Group of Chongqing Expert Consensus on Biologics Treatment for Type 2 Inflammatory Asthma, Respiratory Physician Branch of Chongqing Medical Doctor Association, Respiratory Medicine Management Expert Committee of Chongqing Hospital Management Association, Chongqing Center of Prevention and Treatment for Chronic Respiratory Diseases, Chongqing Center of Medical Quality Control for Respiratory Diseases, GUO Shu-liangGUIDELINE AND CONSENSUS484-4947Interpretation of key updates on NCCN Small Cell Lung Cancer Guidelines(Version 2025)WANG Qi, WANG Jian, JIN Yi-nuoCRITERIA AND INTERPRETATION495-4978Interpretation of the key points in International Expert Consensus on Diagnosis and Treatment of Lung Cancer Complicated by Chronic Obstructive Pulmonary DiseaseYANG Lan, LIU Dan, LI Wei-minCRITERIA AND INTERPRETATION498-5029New strategies and application prospects of lung cancer screening in ChinaLI Sha-sha, ZHANG Rui, LI Wei-minEXPERT FORUM503-50710Clinical characteristics and survival analysis of 43 cases presenting with the coexistence of interstitial lung disease with lung cancerSHEN Lan-ying, ZHANG Yan, HU YueORIGINAL CONTRIBUTION508-514,52111Analysis of prognostic factors in patients with polymyositis or dermatomyositis combined with interstitial lung diseaseLI Jian-bin, LYU Meng-na, LIU Peng-cheng, CHEN Li-ming, WU RuiORIGINAL CONTRIBUTION515-52112Analysis of clinical characteristics of 50 patients with renal immune-related adverse events induced by immune checkpoint inhibitors:a real-world observational studyXUE Zhuo-rui, TENG Fei, HU Rong-rong, AI San-xi, SHI Xiao-xiao, WANG Xiang, SI Xiao-yan, WANG Han-ping, YING Hong-yan, XU Yan, YE Wei, FAN Xiao-hong, LI Xue-mei, ZHENG KeORIGINAL CONTRIBUTION522-532 